Activation therapy for the treatment of inpatients with depression - protocol for a randomised control trial compared to treatment as usual
- PMID: 30709391
- PMCID: PMC6359820
- DOI: 10.1186/s12888-019-2038-2
Activation therapy for the treatment of inpatients with depression - protocol for a randomised control trial compared to treatment as usual
Abstract
Background: Inpatients with depression have a poor long term outcome with high rates of suicide, high levels of morbidity and frequent re-admission. Current treatment often relies on pharmacological intervention and focuses on observation to maintain safety. There is significant neurocognitive deficit which is linked to poor functional outcomes. As a consequence, there is a need for novel psychotherapeutic interventions that seek to address these concerns.
Methods: We combined cognitive activation and behavioural activation to create activation therapy (AT) for the treatment of inpatient depression and conducted a small open label study which demonstrated acceptability and feasibility. We propose a randomised controlled trial which will compare treatment as usual (TAU) with TAU plus activation therapy for adult inpatients with a major depressive episode. The behavioural activation component involves therapist guided re-engagement with previously or potentially rewarding activities. The cognitive activation aspect utilises computer based exercises which have been shown to improve cognitive function.
Discussion: The proposed randomised controlled trial will examine whether or not the addition of this therapy to TAU will result in a reduced re-hospitalisation rate at 12 weeks post discharge. Subjective change in activation and objectively measured change in activity levels will be rated, and the extent of change to neurocognition will be assessed.
Trial registration: Unique trial number: U1111-1190-9517. Australian New Zealand Clinical Trials Registry (ANZCTR) number: ACTRN12617000024347p .
Keywords: Actigraphy; Activation therapy; Cognitive activation; Depression; Inpatient; Neurocognitive; Rehospitalisation rate; Therapy.
Conflict of interest statement
Ethics approval and consent to participate
Ethics approval was granted for the pilot study from the University of Otago Human Ethics Committee (Health) (Approval No: H15/056). Ethical approval for the proposed study was granted on 1 June 2018 (reference [18]/NTB/75) by the Health and Disability Ethics Committees (Northern B), Ministry of Health, 133 Molesworth Street, P.O. Box 5013, Wellington, New Zealand, 6011. All participants provided written informed consent.
Consent for publication
Not applicable.
Competing interests
Professors Porter and Bowie use Software for research at no cost from Scientific Brain Training Pro. Professor Porter has received support for travel to educational meetings from Servier and Lundbeck.
Professor Bowie is a Consultant or Board Member for Takeda, Boehringer Ingelheim, Lundbeck, Otsuka and receives grant Support from Pfizer, Takeda.
All other authors have no competing interests to declare.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
-
- Angst J, Angst F, Stassen HH. Suicide risk in patients with major depressive disorder. J Clin Psychiatry 1999;60 Suppl 2:57–62; discussion 75–6, 113–6. - PubMed
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Research Materials
